Steven Cohen’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.8K Buy
+29,128
New +$32.2K ﹤0.01% 3792
2026
Q2
– Sell
-304,363
Closed -$481K – 4331
2026
Q1
$481K Buy
304,363
+144,955
+91% +$244K ﹤0.01% 3133
2025
Q4
$266K Buy
+159,408
New +$276K ﹤0.01% 3523
2023
Q2
– Sell
-13,786
Closed -$20.7K – 2493
2023
Q1
$20.7K Buy
+13,786
New +$19.2K ﹤0.01% 1966

Other funds holding LCTX

Steven Cohen's LCTX Position: Q3 2026 in Review

Steven Cohen opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 29,128 shares worth $27.8K. The stake represents ﹤0.01% of the portfolio and ranks #3792 among its holdings. This is a return to the name: Steven Cohen previously reported a position in LCTX as recently as Q1 2026.

Steven Cohen first reported a position in LCTX in Q1 2023 and has held it in 4 quarters since. The position peaked at $481K in Q1 2026. 143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Steven Cohen held 29,128 shares of Lineage Cell Therapeutics worth $27.8K as of Q3 2026.
  • Lineage Cell Therapeutics was a new Steven Cohen position in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #3792 holding.
  • Steven Cohen first reported a position in Lineage Cell Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Steven Cohen's Lineage Cell Therapeutics position peaked at $481K in Q1 2026.
  • 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.